Principal Pharmacist at Guy's and St Thomas' NHS Foundation Trust
Chronic obstructive pulmonary disease: clinical phenotypes and implications for managementSubscription
Phenotyping patients with chronic obsructive pulmonary disease allows their separation into distinct categories that differentiate their prognosis and response to treatment, producing clinically meaningful outcomes.
Inhaled corticosteroids: managing side effectsSubscription
Inhaled corticosteroids are commonly prescribed but need careful management to minimise the risk of side effects.
The UK is experiencing an explosion of new drugs and inhaler devices being licensed for people with respiratory disease, increasing the complexity of prescribing for people with asthma or chronic obstructive pulmonary disease (COPD). The management of how these new products are introduced into clinical practice is important because they may vary in type of inhaler device and licensing. One product is DuoRespSpiromax, a cheaper “branded generic” of Symbicort Turbohaler, both containing
Primum non nocereSubscription
Our concerns with Relvar ElliptaSubscription